+7 (701) 759 90 19
USD 423.87 EUR 505.25
RUB 5.59 CNY 64.43
News

Favipiravir permanently registered in Russia for COVID-19 treatment

29 October 2020 21:20
Share in:
Favipiravir permanently registered in Russia for COVID-19 treatment

MOSCOW. KAZINFORM - Favipiravir, a drug used to treat COVID-19, has received permanent registration in Russia, Russian Deputy Health Minister Viktor Fisenko said on Thursday, TASS reports.

Related news
129 COVID-19 cases in schoolchildren reported in Kazakhstan over past week Kazakhstan’s COVID-19 situation worsening – Alexei Tsoi Record high 27,543 cases of COVID-19 infection detected in Russia

«Following a sped-up procedure, we have greenlit circulation of prevention drugs (vaccines), antiviral therapy drugs - Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm - Levilimab,» he said, adding that Favipiravir has received a permanent registration certificate.

Earlier, the Russian Federal Service for Surveillance in Healthcare informed that Russia had registered three drugs based on Favipiravir: Avifavir, Areplivir and Coronavir. The watchdog has not received any complaints of non-specific motor disorders during the use of the drugs.


Share in:
+7
Send
Employees online
Editor
Nurmaganbetova Zhanna
Nurmaganbetova Zhanna
954-048
Editor
Kudrenok Tatyana
Kudrenok Tatyana
954-048
Editor
Seilkhanov Adlet
Seilkhanov Adlet
954-048

Archive